INS and diabetes mellitus: Access to diabetes technology for glycaemic management was limited, with only 4.5% of those eligible having a flash or continuous glucose monitor (CGM) at the baseline, which increased to 89% at the 12‐month follow‐up for individuals with diabetes undergoing haemodialysis and treated with insulin therapy (see Table 3).